

Table S1 Overview of linagliptin Phase 3 clinical trials included in the CV meta-analysis

Study	Treatment	Patients	Background	Follow-up (weeks)	Reference/ NCT #
1218.15	Linagliptin 5 mg Placebo	259 130	Pioglitazone	24	Gomis <i>et al</i> [18] NCT00641043
1218.16	Linagliptin 5 mg Placebo	336 167	None	24	Del Prato <i>et al</i> [16] NCT00621140
1218.17	Linagliptin 5 mg Placebo	523 177	Metformin	24	Taskinen <i>et al</i> [17] NCT00601250
1218.18	Linagliptin 5 mg Placebo	792 263	Metformin + sulphonylurea	24	Owens <i>et al</i> [19] NCT00602472
1218.20	Linagliptin 5 mg Glimepiride 1–4 mg	778 781	Metformin	52*	NCT00622284
1218.23	Linagliptin 5 mg Linagliptin 10 mg Voglibose 0.6 mg Placebo	159 160 162 80	None	26	NCT00654381
1218.35	Linagliptin 5 mg Placebo	161 84	Sulphonylurea	18	NCT00819091
1218.50	Linagliptin 5 mg Placebo [†]	151 76	None	18 [†]	NCT00740051

*Interim analysis at database lock; study continued for further 52 weeks.

[†]Placebo only during 18 weeks; switched to glimepiride for further 34 weeks (in metformin ineligible patients).